Jefferies Financial Group Inc. Invests $1.92 Million in Eton Pharmaceuticals, Inc. $ETON

Jefferies Financial Group Inc. purchased a new stake in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) in the third quarter, Holdings Channel reports. The firm purchased 88,440 shares of the company’s stock, valued at approximately $1,922,000.

Several other institutional investors and hedge funds have also made changes to their positions in the company. State of Alaska Department of Revenue bought a new position in Eton Pharmaceuticals during the third quarter worth $30,000. Ameritas Investment Partners Inc. bought a new stake in Eton Pharmaceuticals during the second quarter valued at $37,000. Legal & General Group Plc bought a new stake in Eton Pharmaceuticals during the second quarter valued at $41,000. Police & Firemen s Retirement System of New Jersey acquired a new stake in shares of Eton Pharmaceuticals during the second quarter worth $87,000. Finally, New York State Common Retirement Fund bought a new position in shares of Eton Pharmaceuticals in the 2nd quarter worth about $115,000. 27.86% of the stock is owned by institutional investors and hedge funds.

Eton Pharmaceuticals Stock Performance

Shares of ETON opened at $18.09 on Thursday. The firm has a fifty day moving average of $16.26 and a 200-day moving average of $17.26. The company has a market cap of $485.17 million, a price-to-earnings ratio of -72.36 and a beta of 1.19. The company has a debt-to-equity ratio of 1.19, a quick ratio of 1.25 and a current ratio of 1.63. Eton Pharmaceuticals, Inc. has a 1 year low of $11.09 and a 1 year high of $23.00.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on ETON. Craig Hallum lifted their price target on shares of Eton Pharmaceuticals from $29.00 to $30.00 and gave the company a “buy” rating in a report on Tuesday, March 3rd. Wall Street Zen lowered shares of Eton Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, December 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Eton Pharmaceuticals in a report on Thursday, January 22nd. HC Wainwright lifted their target price on Eton Pharmaceuticals from $35.00 to $37.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. Finally, Zacks Research raised Eton Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Thursday, January 1st. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Eton Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $31.00.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.